Study of Trastuzumab Deruxtecan (T-DXd) vs Investigator's Choice Chemotherapy in HER2-low, Hormone Receptor Positive, Metastatic Breast Cancer
Public ClinicalTrials.gov record NCT04494425. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Official title
A Phase 3, Randomized, Multi-center, Open-label Study of Trastuzumab Deruxtecan (T-DXd) Versus Investigator's Choice Chemotherapy in HER2-Low, Hormone Receptor Positive Breast Cancer Patients Whose Disease Has Progressed on Endocrine Therapy in the Metastatic Setting (DESTINY-Breast06)
Brief summary
Reproduced verbatim from the official ClinicalTrials.gov record. Not medical advice.
This study will evaluate the efficacy, safety and tolerability of trastuzumab deruxtecan compared with investigator's choice chemotherapy in human epidermal growth factor receptor (HER)2-low, hormone receptor (HR) positive breast cancer patients whose disease has progressed on endocrine therapy in the metastatic setting.
Study identification
- NCT ID
- NCT04494425
- Recruitment status
- Active, not recruiting
- Study type
- Interventional
- Phase
- Phase 3
- Enrollment
- 866 participants
Conditions and interventions
Conditions
Interventions
- Trastuzumab deruxtecan Drug
- Capecitabine Drug
- Paclitaxel Drug
- Nab-Paclitaxel Drug
Drug
Eligibility (public fields only)
- Age range
- 18 Years to 105 Years
- Sex
- All
- Healthy volunteers
- Healthy volunteers not accepted
This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.
Study timeline
- Start date
- Jul 24, 2020 (Actual)
- Primary completion
- Mar 18, 2024 (Actual)
- Completion
- Jun 19, 2026 (Estimated)
- Last update posted
- Mar 4, 2026
2020 – 2026
United States locations
- U.S. sites
- 27
- U.S. states
- 22
- U.S. cities
- 26
| Facility | City | State | ZIP | Site status |
|---|---|---|---|---|
| Research Site | Scottsdale | Arizona | 85259 | — |
| Research Site | Springdale | Arkansas | 72762 | — |
| Research Site | Duarte | California | 91010 | — |
| Research Site | Los Angeles | California | 90017 | — |
| Research Site | Aurora | Colorado | 80045 | — |
| Research Site | Lakewood | Colorado | 80228 | — |
| Research Site | Washington D.C. | District of Columbia | 20016 | — |
| Research Site | Jacksonville | Florida | 32224 | — |
| Research Site | Kansas City | Kansas | 66160 | — |
| Research Site | Louisville | Kentucky | 40202 | — |
| Research Site | Bethesda | Maryland | 20817 | — |
| Research Site | Boston | Massachusetts | 02114 | — |
| Research Site | Detroit | Michigan | 48202 | — |
| Research Site | Rochester | Minnesota | 55905 | — |
| Research Site | St Louis | Missouri | 63110 | — |
| Research Site | Summit | New Jersey | 07901 | — |
| Research Site | Westbury | New York | 11590 | — |
| Research Site | Columbus | Ohio | 43210 | — |
| Research Site | Pittsburgh | Pennsylvania | 15212 | — |
| Research Site | Nashville | Tennessee | 37232 | — |
| Research Site | Austin | Texas | 78731 | — |
| Research Site | Dallas | Texas | 75246 | — |
| Research Site | Houston | Texas | 77030 | — |
| Research Site | Houston | Texas | 77090 | — |
| Research Site | Norfolk | Virginia | 23502 | — |
| Research Site | Seattle | Washington | 98104 | — |
| Research Site | Madison | Wisconsin | 53792-5666 | — |
Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.
Non-U.S. locations
This page focuses on the U.S. directory. The official record also lists 266 non-U.S. sites.
About this trial record page
- What this page shows
- Public field values for ClinicalTrials.gov record NCT04494425, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
- What this page does not do
- No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
- Where the data comes from
- Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
- Last refresh
- Last update posted Mar 4, 2026 · Synced Oct 28, 2026
Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.
Open the official record
The complete public registry record, listed eligibility criteria, and available contact information for NCT04494425 live on ClinicalTrials.gov.